标题
Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
作者
关键词
Custirsen, Clusterin, Prostate cancer, Antisense oligonucleotides, Resistance
出版物
Current Oncology Reports
Volume 15, Issue 2, Pages 113-118
出版商
Springer Nature
发表日期
2012-12-24
DOI
10.1007/s11912-012-0285-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- International Variation in Prostate Cancer Incidence and Mortality Rates
- (2012) Melissa M. Center et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
- (2011) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Patterns of Cancer Incidence and Mortality Rates and Trends
- (2010) A. Jemal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
- (2010) A. Zoubeidi et al. CLINICAL CANCER RESEARCH
- Castration-Resistant Prostate Cancer
- (2010) Giuseppe Di Lorenzo et al. DRUGS
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- The clusterin paradigm in prostate and breast carcinogenesis
- (2009) Federica Rizzi et al. ENDOCRINE-RELATED CANCER
- Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells
- (2009) Federica Rizzi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread
- (2009) S Bettuzzi et al. ONCOGENE
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
- (2008) K. N. Chi et al. CLINICAL CANCER RESEARCH
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel
- (2008) T. M. Sissung et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started